Atypical Neuroleptics Have Low Affinity for Dopamine D2 Receptors or Are Selective for D4 Receptors

[1]  B. Wallin,et al.  P-7-16 Two open-label, long-term safety studies of sertindole , 1996, European Neuropsychopharmacology.

[2]  E. Jerning,et al.  Critical reevaluation of spiperone and benzamide binding to dopamine D2 receptors: evidence for identical binding sites. , 1996, European journal of pharmacology.

[3]  D. Collier,et al.  The dopamine D4 receptor in schizophrenia: an update , 1996, Psychological Medicine.

[4]  S. Schulz,et al.  Efficacy, safety, and dose response of three doses of sertindole and three doses of haldol in schizophrenic patients , 1996, Schizophrenia Research.

[5]  R. Conley,et al.  Dopamine D2, D3, D4 receptors in human postmortem brain sections: Comparison between normals and schizophrenics , 1996, Schizophrenia Research.

[6]  C. Tamminga,et al.  Distribution of dopamine D4 receptor in human postmortem brain sections: Autoradiographic studies with [3H]-NGD-94-1 , 1996, Schizophrenia Research.

[7]  M. Millan,et al.  Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors , 1996, Neuropharmacology.

[8]  P. Seeman,et al.  Dopamine and serotonin receptors: amino acid sequences, and clinical role in neuroleptic parkinsonism. , 1996, Japanese journal of pharmacology.

[9]  C. Tamminga,et al.  D2-Family receptor distribution in human postmortem tissue: an autoradiographic study , 1995, Neuroreport.

[10]  P. Sokoloff,et al.  Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. , 1995, The Journal of pharmacology and experimental therapeutics.

[11]  P. Seeman,et al.  Schizophrenia: elevation of dopamine D4-like sites, using [3H]nemonapride and [125I]epidepride. , 1995, European Journal of Pharmacology.

[12]  P. Seeman,et al.  Deriving the therapeutic concentrations for clozapine and haloperidol: the apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligand. , 1995, European journal of pharmacology.

[13]  J. W. Wells,et al.  Cooperativity Manifest in the Binding Properties of Purified Cardiac Muscarinic Receptors (*) , 1995, The Journal of Biological Chemistry.

[14]  P. Seeman.  Therapeutic receptor-blocking concentrations of neuroleptics. , 1995 .

[15]  D. Casey.  Motor and mental aspects of extrapyramidal syndromes , 1995, International clinical psychopharmacology.

[16]  G. Reynolds,et al.  Absence of detectable striatal dopamine D4 receptors in drug-treated schizophrenia. , 1995, European journal of pharmacology.

[17]  Tomiki Sumiyoshi,et al.  Dopamine D4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression , 1995, Brain Research.

[18]  H. Meltzer,et al.  5HT2-receptor antagonists can attenuate submaximal haloperidol-induced catalepsy in rats , 1995, Schizophrenia Research.

[19]  E. Pehek.  Systemic and intracortical administration of ritanserin increases in vivo dopamine release in rat prefrontal corteX , 1995, Schizophrenia Research.

[20]  I. Creese,et al.  Dopamine D2-like receptors are elevated after chronic treatment with typical and atypical neuroleptics , 1995, Schizophrenia Research.

[21]  I. Creese,et al.  Distinct localization and regulation of dopamine D3 receptors: Autoradiographic studies , 1995, Schizophrenia Research.

[22]  D. Charney,et al.  Spect imaging of striatal dopamine release after amphetamine challenge in humans: Relationship between subjective effects and dopamine release , 1995, Schizophrenia Research.

[23]  P. Seeman,et al.  Long-term haloperidol elevates dopamine D4 receptors by 2-fold in rats. , 1995, European journal of pharmacology.

[24]  M. Matsumoto,et al.  Full-length cDNA cloning and distribution of human dopamine D4 receptor. , 1995, Brain research. Molecular brain research.

[25]  T. Hyde,et al.  Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[26]  M. Huttunen.  The Evolution of the Serotonin‐Dopamine Antagonist Concept , 1995, Journal of clinical psychopharmacology.

[27]  C. Halldin,et al.  D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. , 1995, The American journal of psychiatry.

[28]  H. Meltzer,et al.  Plasma Clozapine Levels and the Treatment of L-DOPA-Induced Psychosis in Parkinson's Disease , 1995, Neuropsychopharmacology.

[29]  J D Brodie,et al.  Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[30]  H. Meltzer,et al.  Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease: A high potency effect of clozapine , 1995 .

[31]  G. Sedvall,et al.  D1-, D2-, and 5-HT2-receptor occupancy in clozapine-treated patients. , 1994, The Journal of clinical psychiatry.

[32]  H. V. Van Tol,et al.  Dopamine D4 receptor repeat: analysis of different native and mutant forms of the human and rat genes. , 1994, Molecular pharmacology.

[33]  M. Millan,et al.  Clozapine inhibits serotoninergic transmission by an action at alpha 1-adrenoceptors not at 5-HT1A receptors. , 1994, European journal of pharmacology.

[34]  Gwenn S. Smith,et al.  The serotonin-dopamine interaction measured with positron emission tomography (PET) and C-11 raclopride in normal human subjects , 1994 .

[35]  D. Sibley,et al.  Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. , 1994, The Journal of pharmacology and experimental therapeutics.

[36]  J S Fowler,et al.  Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[37]  P. Seeman,et al.  Dopamine D4 receptors elevated in schizophrenia , 1993, Nature.

[38]  H. Meltzer,et al.  Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. , 1993, The Journal of pharmacology and experimental therapeutics.

[39]  D. Jackson,et al.  Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. , 1993, Molecular pharmacology.

[40]  I. Kusumi,et al.  Dopamine D1, D2 and serotonin2 receptor occupation by typical and atypical antipsychotic drugs in vivo. , 1993, The Journal of pharmacology and experimental therapeutics.

[41]  J. Hietala,et al.  Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists. , 1993, European journal of pharmacology.

[42]  I. Lucki,et al.  Serotonergic involvement in haloperidol-induced catalepsy. , 1993, The Journal of pharmacology and experimental therapeutics.

[43]  J S Fowler,et al.  Striatal binding of the PET ligand 11C‐raclopride is altered by drugs that modify synaptic dopamine levels , 1993, Synapse.

[44]  P. Seeman.  Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. , 1992, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[45]  P. Garris,et al.  Regulation of transient dopamine concentration gradients in the microenvironment surrounding nerve terminals in the rat striatum , 1992, Neuroscience.

[46]  R. Sunahara,et al.  The cloned dopamine D2 receptor reveals different densities for dopamine receptor antagonist ligands. Implications for human brain positron emission tomography. , 1992, European journal of pharmacology.

[47]  R R MacGregor,et al.  GABAergic inhibition of endogenous dopamine release measured in vivo with 11C-raclopride and positron emission tomography , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[48]  N. Moore,et al.  The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. , 1992, The Journal of pharmacology and experimental therapeutics.

[49]  P. Seeman,et al.  Multiple dopamine D4 receptor variants in the human population , 1992, Nature.

[50]  G. Sedvall,et al.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. , 1992, Archives of general psychiatry.

[51]  Marc Laruelle,et al.  Amphetamine‐stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates , 1992, Synapse.

[52]  W. Fleischhacker,et al.  The effect of ritanserin on treatment-resistant neuroleptic induced akathisia: Case reports , 1992, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[53]  A. Megens,et al.  Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). , 1992, The Journal of pharmacology and experimental therapeutics.

[54]  H. Meltzer,et al.  Effects of antipsychotic drugs on serotonin receptors. , 1991, Pharmacological reviews.

[55]  Jean Logan,et al.  Effects of endogenous dopamine on measures of [18F]N‐methylspiroperidol binding in the basal ganglia: Comparison of simulations and experimental results from PET studies in baboons , 1991, Synapse.

[56]  D. Wong,et al.  Effects of endogenous dopamine on kinetics of [3H]N‐methylspiperone and [3H]raclopride binding in the rat brain , 1991, Synapse.

[57]  Susan R. George,et al.  Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1 , 1991, Nature.

[58]  Philip Seeman,et al.  Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine , 1991, Nature.

[59]  J S Fowler,et al.  Amphetamine induced decreases in (18F)‐N‐methylspiroperidol binding in the baboon brain using positron emission tomography (PET) , 1991, Synapse.

[60]  P. Strange,et al.  pH dependence of sulpiride binding to D2 dopamine receptors in bovine brain. , 1991, Biochemical pharmacology.

[61]  Svante B. Ross,et al.  Synaptic Concentration of Dopamine in the Mouse Striatum in Relationship to the Kinetic Properties of the Dopamine Receptors and Uptake Mechanism , 1991, Journal of neurochemistry.

[62]  S. Marini,et al.  5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. , 1990, Clinical neuropharmacology.

[63]  J. Leysen,et al.  Gaps and peculiarities in 5-HT2 receptor studies. , 1990, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[64]  P. Seeman.  Atypical neuroleptics: role of multiple receptors, endogenous dopamine, and receptor linkage , 1990, Acta psychiatrica Scandinavica. Supplementum.

[65]  T. Högberg,et al.  Potential antipsychotic agents 5. Synthesis and antidopaminergic properties of substituted 5,6-dimethoxysalicylamides and related compounds. , 1990, Journal of medicinal chemistry.

[66]  P. Seeman,et al.  Cloning of two additional catecholamine receptors from rat brain , 1990, FEBS letters.

[67]  B. Gustafsson,et al.  Amperozide--a new putatively antipsychotic drug with a limbic mode of action on dopamine mediated behaviour. , 1990, Pharmacology & toxicology.

[68]  Y. Ohno,et al.  Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions. , 1990, Japanese journal of pharmacology.

[69]  P. Seeman,et al.  Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[70]  D. Hoyer,et al.  Interaction of psychotropic drugs with central 5-HT3 recognition sites: fact or artifact? , 1989, European journal of pharmacology.

[71]  H. Meltzer,et al.  Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. , 1989, The Journal of pharmacology and experimental therapeutics.

[72]  A. Janowsky,et al.  Sterically hindered 5,11-dicarbo analogues of clozapine as potential chiral antipsychotic agents. , 1989, Journal of medicinal chemistry.

[73]  T. Cooper,et al.  Dopamine receptor occupancy and plasma haloperidol levels. , 1989, Archives of general psychiatry.

[74]  P. Hicks.  The effect of serotonergic agents on haloperidol-induced catalepsy , 1989, Schizophrenia Research.

[75]  H. Meltzer,et al.  The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. , 1989, Psychopharmacology bulletin.

[76]  P. Seeman,et al.  Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: Implications for positron emission tomography of the human brain , 1989, Synapse.

[77]  G Honigfeld,et al.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.

[78]  L. Cervo,et al.  8-hydroxy-2-(di-N-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis , 1988, Neuropharmacology.

[79]  D Rodbard,et al.  An exact correction to the "Cheng-Prusoff" correction. , 1988, Journal of receptor research.

[80]  D. Grandy,et al.  Cloning and expression of a rat D2 dopamine receptor cDNA , 1988, Nature.

[81]  P. Seeman,et al.  Dopamine D-2 receptors in canine brain: ionic effects on [3H]neuroleptic binding. , 1987, European journal of pharmacology.

[82]  E. Richelson,et al.  Antagonism by neuroleptics of serotonin 5-HT1A and 5-HT2 receptors of normal human brain in vitro. , 1987, European journal of pharmacology.

[83]  A. M. Friedman,et al.  Exogenous l-dopa alters spiroperidol binding, in vivo, in the mouse striatum. , 1986, Life sciences.

[84]  P. Seeman,et al.  Regulation of Anterior Pituitary D2 Dopamine Receptors by Magnesium and Sodium Ions , 1985, Journal of neurochemistry.

[85]  P. Seeman,et al.  Complete Conversion of Brain D2 Dopamine Receptors from the High‐ to the Low‐Affinity State for Dopamine Agonists, Using Sodium Ions and Guanine Nucleotide , 1985, Journal of neurochemistry.

[86]  J. W. Wells,et al.  Dopamine Receptor Parameters Detected by [3H]Spiperone Depend on Tissue Concentration: Analysis and Examples , 1984, Journal of neurochemistry.

[87]  M. B. Bowers.  Homovanillic acid in caudate and pre-frontal cortex following neuroleptics. , 1984, European journal of pharmacology.

[88]  J. Leysen,et al.  [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. , 1982, Molecular pharmacology.

[89]  C. A. Stone,et al.  Stereospecific antidopaminergic and anticholinergic actions of the enantiomers of (+/-)-1-cyclopropylmethyl-4-(3-trifluoromethylthio-5H-dibenzo[a,d]cyclohepten-5-ylidene) piperidine (CTC), a derivative of cyproheptadine. , 1979, The Journal of pharmacology and experimental therapeutics.

[90]  P. Seeman,et al.  Antipsychotic drug doses and neuroleptic/dopamine receptors , 1976, Nature.

[91]  S H Snyder,et al.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs , 1976, Science.

[92]  P. Seeman,et al.  Brain receptors for antipsychotic drugs and dopamine: direct binding assays. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[93]  S. Snyder,et al.  Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. , 1974, Archives of general psychiatry.

[94]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[95]  N. Andén,et al.  Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system , 1973, The Journal of pharmacy and pharmacology.

[96]  P. Seeman,et al.  The membrane actions of anesthetics and tranquilizers. , 1972, Pharmacological reviews.

[97]  P. Seeman,et al.  Chlorpromazine adsorption to brain regions. , 1971, Biochemical pharmacology.

[98]  P. Seeman,et al.  The displacement of membrane calcium by a local anesthetic (chlorpromazine). , 1969, Biochimica et biophysica acta.

[99]  P. Seeman,et al.  Membrane expansion of the erythrocyte by both the neutral and ionized forms of chlorpromazine. , 1969, Biochimica et biophysica acta.

[100]  P. Seeman,et al.  I. Erythrocyte membrane stabilization by tranquilizers and antihistamines , 1966 .

[101]  P. Seeman.  II. Erythrocyte membrane stabilization by local anesthetics and tranquilizers , 1966 .

[102]  P. Seeman,et al.  Membrane stabilization by drugs: tranquilizers, steroids, and anesthetics. , 1966, International review of neurobiology.

[103]  H. Lauener,et al.  The pharmacological properties of a potent neurotropic compound from the dibenzothiazepine group. , 1965, International journal of neuropharmacology.

[104]  C. Niemegeers,et al.  IS IT POSSIBLE TO PREDICT THE CLINICAL EFFECTS OF NEUROLEPTIC DRUGS (MAJOR TRANQUILLIZERS) FROM ANIMAL DATA?I. "NEUROLEPTIC ACTIVITY SPECTRA" FOR RATS. , 1965, Arzneimittel-Forschung.

[105]  P. Seeman,et al.  THE SURFACE ACTIVITY OF TRANQUILIZERS. , 1963, Biochemical pharmacology.